Shannon N. Westin
A5026269100- Ovarian cancer diagnosis and treatment
- Endometrial and Cervical Cancer Treatments
- PARP inhibition in cancer therapy
- Cancer Genomics and Diagnostics
- BRCA gene mutations in cancer
- PI3K/AKT/mTOR signaling in cancer
- Endometriosis Research and Treatment
- Uterine Myomas and Treatments
- Intraperitoneal and Appendiceal Malignancies
- Cancer Immunotherapy and Biomarkers
- RNA Research and Splicing
- Genetic factors in colorectal cancer
- Renal cell carcinoma treatment
- Estrogen and related hormone effects
- Cervical Cancer and HPV Research
- DNA and Nucleic Acid Chemistry
- Cancer Mechanisms and Therapy
- Cancer survivorship and care
- Economic and Financial Impacts of Cancer
- Advanced Breast Cancer Therapies
- Reproductive Biology and Fertility
- Cancer, Lipids, and Metabolism
- Cancer-related molecular mechanisms research
- Reproductive System and Pregnancy
- Colorectal Cancer Surgical Treatments
The University of Texas MD Anderson Cancer Center
2016-2025
Gynecologic Oncology Group
2015-2022
American Society of Clinical Oncology
2018-2020
Bayer (France)
2020
National Cancer Institute
2018-2020
Dana-Farber Cancer Institute
2013-2020
Memorial Sloan Kettering Cancer Center
2013-2020
Acceleron Pharma (United States)
2020
Astellas Pharma (United Kingdom)
2020
Janssen (Belgium)
2020
Mutations of the PIK3CA gene may predict response to phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target rapamycin (mTOR) inhibitors. Concomitant mutations in mitogen-activated protein kinase (MAPK) pathway mediate resistance.Tumors from patients with breast, cervical, endometrial, and ovarian cancer referred Clinical Center for Targeted Therapy (Phase I Program) were analyzed PIK3CA, KRAS, NRAS, BRAF mutations. Patients treated, whenever feasible, agents targeting PI3K/AKT/mTOR...
Purpose NRG Oncology/RTOG 1203 was designed to compare patient-reported acute toxicity and health-related quality of life during treatment with standard pelvic radiation or intensity-modulated therapy (IMRT) in women cervical endometrial cancer. Methods Patients were randomly assigned four-field (RT) IMRT treatment. The primary end point change GI from baseline the RT, measured bowel domain Expanded Prostate Cancer Index Composite (EPIC). Secondary points included urinary toxicity,...
Purpose AKT1 E17K mutations are oncogenic and occur in many cancers at a low prevalence. We performed multihistology basket study of AZD5363, an ATP-competitive pan-AKT kinase inhibitor, to determine the preliminary activity AKT inhibition AKT-mutant cancers. Patients Methods Fifty-eight patients with advanced solid tumors were treated. The primary end point was safety; secondary points progression-free survival (PFS) response according Response Evaluation Criteria Solid Tumors (RECIST)....
ATHENA (ClinicalTrials.gov identifier: NCT03522246) was designed to evaluate rucaparib first-line maintenance treatment in a broad patient population, including those without BRCA1 or BRCA2 (BRCA) mutations other evidence of homologous recombination deficiency (HRD), high-risk clinical characteristics such as residual disease. We report the results from ATHENA-MONO comparison versus placebo. Patients with stage III-IV high-grade ovarian cancer undergoing surgical cytoreduction (R0/complete...
Endometrial cancer is the most common gynecological malignancy, with more than 280,000 cases occurring annually worldwide. Although previous studies have identified important somatic mutations in endometrial cancer, they primarily focused on a small set of known genes and thus provided limited view molecular basis underlying this disease. Here we developed an integrated systems-biology approach to identifying novel contributing tumorigenesis. We first performed whole-exome sequencing 13...
Mutant RAS has remained recalcitrant to targeted therapy efforts. We demonstrate that combined treatment with poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors and mitogen-activated protein kinase (MAPK) (MEK) evokes unanticipated, synergistic cytotoxic effects in vitro vivo multiple mutant tumor models across lineages where mutations are prevalent. The of PARP MEK inhibitor combinations independent BRCA1/2 p53 mutation status, suggesting the activity is likely be...
Immunotherapy and chemotherapy combinations have shown activity in endometrial cancer, with greater benefit mismatch repair (MMR)-deficient (dMMR) than MMR-proficient (pMMR) disease. Adding a poly(ADP-ribose) polymerase inhibitor may improve outcomes, especially pMMR
Abstract Immune checkpoint inhibitors are associated with immune-related adverse events (irAEs), including arthritis (arthritis-irAE). Management of arthritis-irAE is challenging because immunomodulatory therapy for should not impede antitumor immunity. Understanding the mechanisms critical to overcome this challenge, but pathophysiology remains unknown. Here, we comprehensively analyze peripheral blood and/or synovial fluid samples from 20 patients arthritis-irAE, and unmask a prominent...
To understand the mechanism of acquired resistance to poly(ADP-ribose) polymerase inhibitors (PARPi) olaparib, we induced formation polyploid giant cancer cells (PGCCs) in ovarian and breast cell lines, high-grade serous (HGSC)-derived organoids, patient-derived xenografts (PDXs). Time-lapse tracking revealed that PGCCs primarily developed from endoreplication after exposure sublethal concentrations olaparib. exhibited features senescent but, olaparib withdrawal, can escape senescence via...
Endometrial carcinoma in the lower uterine segment (LUS) is a poorly described cancer that can be clinically confused with endocervical carcinoma. We performed case-comparison study to document clinicopathologic characteristics of LUS tumors and their association risk factors for endometrial cancer.The clinical records pathology reports from women who underwent hysterectomy at our institution or adenocarcinoma over an 11-year interval were reviewed. The group consisted clearly originated...
To assess efficacy of the levonorgestrel-releasing intrauterine device (LNG-IUD) for treatment complex atypical hyperplasia or low-grade endometrial cancer.
Shortly before I was elected President of ASCO, attended the 65th birthday party a current patient. She had been diagnosed 10 years earlier with metastatic breast cancer and hadn't sure she wanted to move forward further treatment. With encouragement, participate in clinical trial an investigational drug that is now widely used treat cancer. Happily, here we were, celebrating her now-married daughters, their husbands, three beautiful grandchildren, ages 2, 4, 8. Such importance trials...
A MESSAGE FROM ASCO'S PRESIDENT I remember when ASCO first conceived of publishing an annual report on the most transformative research occurring in cancer care. Thirteen reports later, progress we have chronicled is remarkable, and this year no different. The featured ASCO's Clinical Cancer Advances 2018 underscores impressive gains our understanding ability to tailor treatments tumors' genetic makeup. Advance Year, adoptive cell immunotherapy, allows clinicians genetically reprogram...
Abstract Purpose: This phase I, open-label study (Study 1, D3610C00001; NCT01226316) was the first-in-human evaluation of oral AZD5363, a selective pan-AKT inhibitor, in patients with advanced solid malignancies. The objectives were to investigate safety, tolerability, and pharmacokinetics define recommended dosing schedule, evaluate preliminary clinical activity. Experimental Design: Patients aged ≥18 years World Health Organization (WHO) performance status 0 1. Dose escalation conducted...
In oncology trials, the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) is standard tool reporting adverse events (AEs), but it may underreport symptoms experienced by patients. This analysis of NRG Oncology RTOG 1203 compared symptom patients and clinicians during radiotherapy (RT).Patients with cervical or endometrial cancer requiring postoperative RT were randomly assigned to 4-field intensity-modulated (IMRT). Patients completed 6-item patient-reported...